CRISPR-Cas9
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a groundbreaking gene editing technology that was developed in 2012, following the earlier techniques of ZFN (Zinc Finger) in 2006 and TALEN (Transcription Activator-Like Effector Nucleases) in 2011. With its numerous advantages over existing gene editing technologies, CRISPR has gained widespread adoption among researchers and scientists worldwide.
Benefit of CRISPR
Convenience
One of the key advantages that sets CRISPR apart from ZFN and TALEN is its user-friendliness. Unlike ZFN and TALEN, which require customized proteins designed for each individual gene, CRISPR utilizes RNA molecules and the Cas9 protein to easily manipulate specific genes of interest. The process of designing and producing the proteins needed for ZFN and TALEN is challenging and complex, whereas the CRISPR system is much more accessible and straightforward for researchers.
Efficiency
CRISPR has been proven to be much faster and more efficient than ZFN and TALEN. The process of using CRISPR to edit genes can be completed in a matter of weeks, whereas ZFN and TALEN can take several months or even years to generate the necessary proteins and complete the editing process. Thanks to this speed and efficiency, CRISPR is widely used by numerous researchers and has paved the way for faster advancements in the field of biotechnology.
Due to its ease of use, speed, and efficiency, CRISPR has become a popular gene editing technology. Compared to ZFN and TALEN, CRISPR has been demonstrated to be a more accessible, precise, and effective method for editing genes, opening new avenues for research and development in the field of biotechnology. ToolGen is harnessing the benefits of CRISPR technology, which possesses these advantages, to commercialize it across various fields.
Extended Research
With the unprecedented success of CRISPR-Cas9 technology in the field of gene editing, numerous new CRISPR-based tools have emerged through subsequent research, including Base editors and Prime editors. These tools, each based on Cas9, significantly facilitate gene editing depending on the specific purpose. As Cas9-based tools, the CRISPR-Cas9 original patent holds importance, and ToolGen is engaged in various research and development activities to expand its range of original technology.